Correlation Between Bone Biologics and Neuropace

Can any of the company-specific risk be diversified away by investing in both Bone Biologics and Neuropace at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bone Biologics and Neuropace into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bone Biologics Corp and Neuropace, you can compare the effects of market volatilities on Bone Biologics and Neuropace and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bone Biologics with a short position of Neuropace. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bone Biologics and Neuropace.

Diversification Opportunities for Bone Biologics and Neuropace

-0.46

Correlation Coefficient

Bone Biologics  Neuropace

Very good diversification

The 3 months correlation between Bone and Neuropace is -0.46. Overlapping area represents the amount of risk that can be diversified away by holding Bone Biologics Corp and Neuropace in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neuropace and Bone Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bone Biologics Corp are associated (or correlated) with Neuropace. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neuropace has no effect on the direction of Bone Biologics i.e., Bone Biologics and Neuropace go up and down completely randomly.

Pair Corralation between Bone Biologics and Neuropace

Given the investment horizon of 90 days Bone Biologics Corp is expected to generate 3.7 times more return on investment than Neuropace. However, Bone Biologics is 3.7 times more volatile than Neuropace. It trades about 0.07 of its potential returns per unit of risk. Neuropace is currently generating about 0.12 per unit of risk. If you would invest  116.00  in Bone Biologics Corp on August 31, 2024 and sell it today you would earn a total of  10.00  from holding Bone Biologics Corp or generate 8.62% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Bone Biologics Corp  vs.  Neuropace

Bone Biologics Corp

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Bone Biologics Corp are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak essential indicators, Bone Biologics reported solid returns over the last few months and may actually be approaching a breakup point.

Neuropace

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Neuropace are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady fundamental indicators, Neuropace exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Bone Biologics and Neuropace

The main advantage of trading using opposite Bone Biologics and Neuropace positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bone Biologics position performs unexpectedly, Neuropace can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuropace will offset losses from the drop in Neuropace's long position.

The idea behind Bone Biologics Corp and Neuropace pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.